Epilepsy Therapeutic Market in APAC 2017-2021 with Eisai, GlaxoSmithKline, Pfizer & UCB Dominating - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Epilepsy Therapeutic Market in APAC 2017-2021" report to their offering.

The epilepsy therapeutic market in APAC to grow at a CAGR of 4.25% during the period 2017-2021.

Epilepsy Therapeutic Market in APAC 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the sales of branded, generic, and off label drugs.

The latest trend gaining momentum in the market is reformulation of marketed drugs. Drug delivery systems such as transdermal patches, extended-release (ER) formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of the drug. The reformulation of marketed drugs also provides an opportunity to grab patent term extensions, which can delay the entry of generic versions in the market.

According to the report, one of the major drivers for this market is high unmet medical need. The epilepsy therapeutics market in APAC is currently witnessing a high unmet medical need in terms of the lack of any disease-modifying treatment.

Key vendors

  • Eisai
  • GlaxoSmithKline
  • Pfizer
  • UCB

Other prominent vendors

  • Dainippon Sumitomo Pharma
  • Janssen Pharmaceutical (a division of Johnson & Johnson)

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Market landscape

Part 07: Pipeline analysis

Part 08: Market segmentation based on product type

Part 09: Geographical segmentation

Part 10: Decision framework

Part 11: Drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

Part 15: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/hqqz7d/epilepsy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs